Skip to content
Editorial Open access

Navigating the nexus: synergistic challenges in diabetes, hypertension, and renal medicine

Aug 2026 · Renal Failure · Vol 48 · 0 citations · 5 references
Medicine

TL;DR

The studies assembled in Renal Failure address challenges from complementary perspectives, spanning acute clinical biomarkers, dialysis outcomes, nutritional epidemiology, cellular therapeutics, and epigenetic regulation.

Abstract

Chronic kidney disease (CKd) has become one of the defining global health challenges of the modern era, driven largely by the parallel epidemics of diabetes mellitus and hypertension. together, these conditions account for the majority of progressive kidney disease worldwide and are increasingly recognized not as isolated diagnoses, but as tightly interconnected processes that amplify vascular injury, metabolic stress, inflammation, and nephron loss. diabetes accelerates glomerular hyperfiltration, oxidative stress, and structural damage, while hypertension compounds endothelial dysfunction, proteinuria, and progressive fibrosis. their coexistence creates a clinical nexus in which renal decline is often faster, cardiovascular risk higher, and therapeutic complexity greater than with either condition alone. this article collection in Renal Failure arrives at an important time. despite substantial advances in reno-protective therapies—including renin–angiotensin system blockade, mineralocorticoid receptor antagonism, and sodium-glucose cotransporter-2 (SGlt2) inhibitors—the burden of CKd attributable to diabetes and hypertension continues to rise. Clinicians increasingly face questions that extend beyond simple blood pressure or glycaemic thresholds: how can risk be detected earlier, outcomes predicted more accurately, metabolic instability reduced, and molecular pathways interrupted before irreversible fibrosis develops? the studies assembled in this collection address these challenges from complementary perspectives, spanning acute clinical biomarkers, dialysis outcomes, nutritional epidemiology, cellular therapeutics, and epigenetic regulation. a particularly notable contribution is the study by lin and colleagues examining the stress hyperglycemia ratio (SHr) as a predictor of acute kidney injury (

Read PDF

Similar papers

Review Open access Oct 2026

Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives

Diabetic kidney disease (DKD) is among the most common and severe microvascular complications of diabetes and represents a leading cause of end-stage renal disease (ESRD) worldwide. Currently, although strict glycemic and blood pressure control, together with the use of renin–angiotensin system inhibitors, sodium-gluco...

Xu-Hao Li, Ya-Miao Wu, Ye Shi et al. · 0 citations
Review Open access Oct 2026

Chronic Kidney Disease: Current Insights into Epidemiology, Molecular Mechanisms, Biomarkers and Management

Chronic Kidney Disease (CKD) affects approximately 14% of adults globally and is a progressive, multifactorial disorder of the kidney characterized by structural or functional nephron impairment. CKD has been linked with several other comorbidities, including diabetes, hypertension, obesity, and aging, which increase t...

Dinesh Bhattarai, C. Nwaduru, R. Cardoso et al. · 0 citations
Review Open access Oct 2026

The Cardiometabolic Triad of Diabetes, Obesity, and Hypertension: Genetic and Pathophysiological Insights

Diabesotension, the coexistence of diabetes mellitus, obesity, and hypertension, represents an increasingly prevalent and clinically significant cardiometabolic syndrome. Epidemiological evidence highlights strong bidirectional relationships among these conditions, which together markedly elevate the risk of cardiovasc...

S. Apparow, Muhammad Asyaari Zakaria, Muhammad Zam Hazri Zamri et al. · 0 citations
Review Open access Oct 2026

Hypertension in The Development and Progression of Diabetic Kidney Disease: A Literature Review

ABSTRACT Diabetic kidney disease (DKD) is one of the leading causes of chronic kidney disease and end‑stage kidney disease worldwide, with hypertension functioning both as a consequence of diabetic renal injury and as a major upstream determinant of its development and progression. This literature review aims to synthe...

Maya Safira, Naufal Gusti · 0 citations
Review Oct 2026

Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease and Type 2 Diabetes: A Narrative Review.

Type 2 diabetes is the leading cause of chronic kidney disease worldwide, and for decades renin-angiotensin-system (RAAS) blockade was the only proven strategy to slow its progression. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have since been shown to slow kidney function decline and reduce cardiorenal events t...

Akshat Banga, P. Deedwania · 0 citations
Review Open access Oct 2026

SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives

The pathophysiological mechanisms underlying DKD are summarized, the mechanistic rationale for integrating SGLT2 inhibitors with exercise is examined, and emerging experimental and clinical evidence regarding their potential effects on renal function, metabolic control, cardiovascular health, and exercise capacity is d...

Hua-Juan Li, Ming-Xian Ai, Xiang-Yu He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.